Completed PHASE2 INTERVENTIONAL 2-arm NCT01144949

Study of Silodosin to Facilitate Passage of Urinary Stones

A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage

Sponsor: Watson Pharmaceuticals

Conditions Kidney Stones Ureteral Calculi Urolithiasis

Updated 2 times since 2024 Last updated: Jul 21, 2014 Started: Jun 30, 2010 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01144949, this PHASE2 trial focuses on Kidney Stones and Ureteral Calculi and remains completed. Sponsored by Watson Pharmaceuticals, it has been updated 2 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Watson Pharmaceuticals

Data source: Watson Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Anchorage, United States , Bala-Cynwyd, United States , Birmingham, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Daytona Beach, United States , Gainesville, United States , Garden City, United States and 17 more locations